SCHEMBL22648259

SCHEMBL22648259

Cc1nn(CCN2CCOCC2)cc1N

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KEAP1 Q14145 1/20 0.38
MAPT P10636 1/20 0.38
LMNA P02545 1/20 0.38
HSP90AA1 P07900 1/20 0.38
TLR8 Q9NR97 2/20 0.37
TLR7 Q9NYK1 2/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
FGFR1 P11362 2/20 0.37
FGFR4 P22455 2/20 0.37
PLK1 P53350 1/20 0.36
FGFR2 P21802 1/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
FLT3 P36888 1/20 0.36
NR5A2 O00482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22648417 0.92 MAPT (0.43) SMN1; SMN2KEAP1MAPTLMNATLR8
SCHEMBL22648413 0.87 DRD2 (0.37) TLR8TLR7
SCHEMBL22648258 0.85 DRD2 (0.39)
SCHEMBL21266800 0.83 POLB (0.40) CNR2SMN1; SMN2LMNAPOLB
SCHEMBL27087768 0.81 TSHR (0.40) CNR2SMN1; SMN2LMNAFGFR1FGFR2
SCHEMBL21602959 0.79 MEN1 (0.38) CNR2LMNAPLK1NR5A2
SCHEMBL22648375 0.77 HRH3 (0.40) TLR8TLR7
SCHEMBL21961340 0.77 S1PR1 (0.42) CNR2HDAC3HDAC1HDAC2MAPK1
SCHEMBL19441806 0.76 SIGMAR1 (0.41) SMN1; SMN2KEAP1MAPTLMNAFGFR1
SCHEMBL22648408 0.76 HRH3 (0.42) TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-10-26 US disclosed
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-10-26 US disclosed
EP-3966206-B1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS LLC (US) 2023-08-09 EP disclosed
US-11590134-B2 Aminopyrimidine amide autophagy inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2023-02-28 US disclosed
US-20230047915-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-02-16 US disclosed
US-11518758-B2 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2022-12-06 US disclosed
US-20210128556-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2021-05-06 US disclosed
US-20200354346-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2020-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128556-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 CNR2 4057/4885SMN1; SMN2 3557/4885KEAP1 503/4885
US-11590134-B2 Aminopyrimidine amide autophagy inhibitors and methods of use thereof BECN1, SQSTM1, ATG7 CNR2 4057/4885SMN1; SMN2 3557/4885KEAP1 503/4885
US-20230047915-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 CNR2 3645/4885SMN1; SMN2 3749/4885KEAP1 665/4885
US-20200354346-A1 HETEROARYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 CNR2 3645/4885SMN1; SMN2 3749/4885KEAP1 665/4885
US-11518758-B2 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof BECN1, SQSTM1, ATG7 CNR2 3645/4885SMN1; SMN2 3749/4885KEAP1 665/4885
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 CNR2 4057/4885SMN1; SMN2 3557/4885KEAP1 503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.